Skin and soft tissue infections in cirrhotics: a prospective analysis of clinical presentation and factors affecting outcome.
Ajit Sood, Vandana Midha, Omesh Goyal...
https://pubmed.ncbi.nlm.nih.gov/24706053/Actively Recruiting
Led by Azienda Sanitaria Locale di Asti · Updated on 2026-04-13
124
Participants Needed
1
Research Sites
21 weeks
Total Duration
This research investigates the use of a structured telenursing program for women with breast cancer receiving cyclin-dependent kinase CDK inhibitor therapy. These treatments can cause side effects that reduce treatment adherence and quality of life. The study aims to determine if scheduled remote nursing follow-ups can help detect and manage these side effects earlier to improve clinical outcomes and reduce complications such as hospital visits and treatment interruptions. Participants are randomly assigned to receive either standard nursing care or standard care plus a structured telenursing intervention. The telenursing program involves scheduled telephone or video consultations at set times during treatment cycles, where trained nurses assess symptoms, provide education, support medication adherence, and identify early signs of treatment toxicities. When significant issues arise, patients are referred promptly to physicians for further management. During the study, participants undergo regular assessments of side effects, treatment adherence, hospital visits, and quality of life using questionnaires and clinical data collected at baseline and throughout up to six months of treatment. The study measures the incidence and severity of adverse events, emergency visits, hospitalizations, and patient-reported outcomes to evaluate the effectiveness of the telenursing intervention compared to standard care.
CONDITIONS
Telenursing for the Early Detection and Management of Side Effects Associated With Cyclin-Dependent Kinase Inhibitors in Breast Cancer Patients
M
MANUELA CANICATTI', RN, MSc, PhD(c)
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Azienda Sanitaria Locale di Asti
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 6 months
Participants receive treatment with cyclin-dependent kinase inhibitors. Those in the telenursing group additionally participate in scheduled remote nursing follow-up to monitor symptoms, manage side effects, and support treatment adherence.
Scheduled outpatient visits per standard care plus scheduled remote nursing contacts approximately at days 7, 14, and 21 of each treatment cycle for the telenursing group
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
SUPPORTIVE_CARE
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Ajit Sood, Vandana Midha, Omesh Goyal...
https://pubmed.ncbi.nlm.nih.gov/24706053/N Bryce Robinson, Mario Gaudino
https://pubmed.ncbi.nlm.nih.gov/33958197/Azar Yahyaei, Tahereh Madani, Samira Vesali...
https://pubmed.ncbi.nlm.nih.gov/39472511/Ching-Yun Hsieh, Ching-Chan Lin, Yu-Wen Huang...
https://pubmed.ncbi.nlm.nih.gov/36264639/Laetitia Courtin-Tanguy, Michel Rayar, Damien Bergeat...
https://pubmed.ncbi.nlm.nih.gov/26776934/Azienda Sanitaria Locale di Asti
Lead Sponsor